179 related articles for article (PubMed ID: 6601736)
1. Subsets of oncofetal antigen-induced T-cells: ability to mediate antitumor immune response.
Gautam S; Deodhar SD
J Natl Cancer Inst; 1983 May; 70(5):923-30. PubMed ID: 6601736
[TBL] [Abstract][Full Text] [Related]
2. T-cell-mediated antitumor immune response induced by oncofetal antigens.
Gautam S; Deodhar SD
J Natl Cancer Inst; 1981 Oct; 67(4):939-45. PubMed ID: 6974275
[TBL] [Abstract][Full Text] [Related]
3. In vitro differentiation of T-cells capable of mediating the regression of established syngeneic tumors in mice.
Shu S; Chou T; Rosenberg SA
Cancer Res; 1987 Mar; 47(5):1354-60. PubMed ID: 3102046
[TBL] [Abstract][Full Text] [Related]
4. Immune selection in murine tumors. Ph.d thesis.
Svane IM; Engel AM
APMIS Suppl; 2003; (106):1-46. PubMed ID: 12739251
[TBL] [Abstract][Full Text] [Related]
5. Some characteristics of the cyclophosphamide-induced immunopotentiating cells in the spleen of mice bearing a large MOPC-315 tumor.
Mokyr MB; Ye QW
Cancer Res; 1985 Oct; 45(10):4932-9. PubMed ID: 4027979
[TBL] [Abstract][Full Text] [Related]
6. Potent effector function of tumor-sensitized L-selectin(low) T cells against subcutaneous tumors requires LFA-1 co-stimulation.
Seeley BM; Barthel SW; To WC; Kjaergaard J; Shu S; Plautz GE
Otolaryngol Head Neck Surg; 2001 Apr; 124(4):436-41. PubMed ID: 11283503
[TBL] [Abstract][Full Text] [Related]
7. Characterization of effector cells mediating antitumor activity in spleen cells of tumor-bearing mice.
Fuyama S; Yamamoto H; Arai S
Cancer Res; 1985 Sep; 45(9):4103-8. PubMed ID: 3875404
[TBL] [Abstract][Full Text] [Related]
8. Importance of Lyt-2+ T-cells in the resistance of melphalan-cured MOPC-315 tumor bearers to a challenge with MOPC-315 tumor cells.
Barker E; Mokyr MB
Cancer Res; 1988 Sep; 48(17):4834-42. PubMed ID: 3261626
[TBL] [Abstract][Full Text] [Related]
9. The mechanism of tumor growth inhibition by tumor-specific Lyt-1+2-T cells. I. Antitumor effect of Lyt-1+2-T cells depends on the existence of adherent cells.
Fujiwara H; Takai Y; Sakamoto K; Hamaoka T
J Immunol; 1985 Sep; 135(3):2187-91. PubMed ID: 3874911
[TBL] [Abstract][Full Text] [Related]
10. Augmentation of antitumor immune responses after adoptive transfer of bone marrow derived from donors immunized with tumor lysate-pulsed dendritic cells.
Asavaroengchai W; Kotera Y; Koike N; Pilon-Thomas S; Mulé JJ
Biol Blood Marrow Transplant; 2004 Aug; 10(8):524-33. PubMed ID: 15282530
[TBL] [Abstract][Full Text] [Related]
11. Analysis of murine oncofetal antigens as tumor-associated transplantation antigens.
Chism SE; Wallis S; Burton RC; Warner NL
J Immunol; 1976 Nov; 117(5 Pt.2):1870-7. PubMed ID: 993583
[TBL] [Abstract][Full Text] [Related]
12. In vitro stimulation and inhibition of tumor cell growth mediated by different lymphoid cell populations.
Norbury KC
Cancer Res; 1977 May; 37(5):1408-15. PubMed ID: 66982
[TBL] [Abstract][Full Text] [Related]
13. A syngeneic metastatic tumor model in mice: the natural immune response of the host and its manipulation.
Treves AJ; Cohen IR; Feldman M
Isr J Med Sci; 1976; 12(4-5):369-84. PubMed ID: 1084880
[TBL] [Abstract][Full Text] [Related]
14. [Enhanced antitumor effects induced by lymphotactin gene-modified dendritic cells after pulsed with tumor antigen peptide].
Zhang W; He L; Cao X
Zhonghua Yi Xue Za Zhi; 1999 Mar; 79(3):170-3. PubMed ID: 11601032
[TBL] [Abstract][Full Text] [Related]
15. Importance of cyclophosphamide-induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice.
Proietti E; Greco G; Garrone B; Baccarini S; Mauri C; Venditti M; Carlei D; Belardelli F
J Clin Invest; 1998 Jan; 101(2):429-41. PubMed ID: 9435316
[TBL] [Abstract][Full Text] [Related]
16. Successful adoptive immunotherapy of murine poorly immunogenic tumor with specific effector cells generated from gene-modified tumor-primed lymph node cells.
Tanaka H; Yoshizawa H; Yamaguchi Y; Ito K; Kagamu H; Suzuki E; Gejyo F; Hamada H; Arakawa M
J Immunol; 1999 Mar; 162(6):3574-82. PubMed ID: 10092816
[TBL] [Abstract][Full Text] [Related]
17. Adoptive immunotherapy with tumor-specific T lymphocytes generated from cytokine gene-modified tumor-primed lymph node cells.
Ohno K; Yoshizawa H; Tsukada H; Takeda T; Yamaguchi Y; Ichikawa K; Maruyama Y; Suzuki Y; Suzuki E; Arakawa M
J Immunol; 1996 May; 156(10):3875-81. PubMed ID: 8621926
[TBL] [Abstract][Full Text] [Related]
18. Role of T-cells in the mechanism of reactivity of the microplate leukocyte adherence inhibition assay.
Raina S; Russo AJ; Jenkins D; Goldrosen MH
Cancer Res; 1981 Oct; 41(10):3950-5. PubMed ID: 6456811
[TBL] [Abstract][Full Text] [Related]
19. Vaccine therapy of established tumors in the absence of autoimmunity.
Hodge JW; Grosenbach DW; Aarts WM; Poole DJ; Schlom J
Clin Cancer Res; 2003 May; 9(5):1837-49. PubMed ID: 12738742
[TBL] [Abstract][Full Text] [Related]
20. Regulation of the immune response to tumor antigens. IX. In vitro Lyt-1+2- cell proliferative responses to cellbound or subcellular tumor antigen.
Carter RH; Drebin JA; Schatten S; Perry LL; Greene MI
J Immunol; 1983 Feb; 130(2):997-1002. PubMed ID: 6184410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
